Severe intestinal graft-versus-host disease following autologous stem cell transplantation [4]

Bone Marrow Transplantation

Volumn 38, Issue 5, 2006, Pages 391-392

  Kline, J ^a   van Besien, K ^a   Nathanson, J ^a   Noffsinger, A ^a   Artz, A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ANOREXIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CERVICAL LYMPH NODE; CLINICAL FEATURE; COLITIS; COLONOSCOPY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINAL DYSMOTILITY; LETTER; LYMPH NODE BIOPSY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; TENESMUS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

DIARRHEA; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INTESTINAL DISEASES; MIDDLE AGED; PREDNISONE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 33747368530     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705460     Document Type: Letter

References (10)

1. Jones RJ, Hess AD, Mann RB, Piantadosi S, Vogelsang GB, Farmer ER et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 333: 754-757.
2. Hood AF, Vogelsang GB, Black LP, Farmer ER, Santos GW. Acute graft-vs-host disease. Development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987; 123: 745-750.
3. + purified autologous peripheral blood progenitor cell transplantation. J Hematother Stem Cell Res 2000; 9: 375-379.
4. Holmberg L, Kikuchi K, Gooley T, Adams KM, Schoch GH, Bensinger WI et al. Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: Incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2006; 12: 226-234.
5. Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Altomonte V, Hess AD et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031-3035.
6. Kennedy MJ, Vogelsang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1993; 11: 478-484.
7. Baron F, Gothot A, Salmon JP, Hermanne JP, Pierard GE, Fillet G et al. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. Br J Haematol 2000; 111: 745-753.
8. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K et al. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 1997; 15: 667-673.
9. van der Wall E, Horn T, Bright E, Passos-Coehlo JL, Bond S, Clarke B et al. Autologous graft-versus-host disease induction in advanced breast cancer: Role of peripheral blood progenitor cells. Br J Cancer 2000; 83: 1405-1411.
10. Saunders MD, Shulman HM, Murakami CS, Chauncey TR, Bensinger WI, McDonald GB. Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. Am J Surg Pathol 2000; 24: 1004-1008.